Top of this page
Skip navigation, go straight to the content
if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition you can contact us using the webform available here
As part of our commitment to patients and to further the understanding of severe diseases, UCB supports a number of programmes for patients and their families. These schemes include sponsorship programmes, informative websites, mentoring projects and scholarships, all of which work towards improving the quality of life for those affected by severe diseases.
Epilepsy Advocates are people living with epilepsy and caregivers seeking the best treatment for controlling their seizures with minimal side effects.
By sharing their personal success stories online and within local communities, Epilepsy Advocates strive to inspire others.
Through these interactions, epilepsy community members can learn from one another and make positive changes in their lives.
Canine Assistants was founded in Alpharetta, Georgia, in 1991. This nonprofit organization is dedicated to providing service dogs to children and adults with epilepsy, physical disabilities, and other special needs.
Seizure response dogs:
These dogs not only provide assistance, they can instill confidence by enabling their recipient to do activities they may be reluctant to do because they have epilepsy. They also provide companionship and contribute to the overall emotional well-being of the person they are placed with.
Seizure response dogs immediately change lives for their owners, but their extensive training can take up to 18 months.
That's why Canine Assistants work together with The Epilepsy CompanyTM, UCB, Inc. in the training of every dog. Their partnership ensures that each dog gets the extensive training that it needs, and that more needs of the epilepsy community are met.
UCB, Inc. is committed to building the lives of US epilepsy patients and their family members/caregivers. This scholarship provides financial support for epilepsy patients or family members/caregivers who demonstrate academic and personal achievement.
The Parkinson's Well-Being Map™ is a tool to help you to prepare for consultations with your healthcare team, so that you can help them to understand how living with Parkinson’s disease affects you.
The Map allows you to record and monitor your Parkinson’s symptoms. It covers all aspects of Parkinson’s, so that you can highlight the symptoms that are of most concern to you and list the key questions to ask at your next consultation. This way, you can ensure that symptoms do not get forgotten or overlooked.
This monitor can help you to improve the communication with your doctor.
Only if your doctor properly understands how you are doing, can he/she treat or manage your RLS in an optimal way.
UCB's initiative focused on Family Planning and Pregnancy in Immunological Diseases aims to bridge knowledge gaps.
UCB has launched an innovative initiative to enhance awareness and improve understanding about family planning and pregnancy in immunological diseases such as rheumatoid arthritis, Crohn’s disease and lupus.
As a leading biopharmaceutical company UCB is committed to helping people with severe immunological diseases to lead active and fulfilling lives and we are proud to contribute to research, development and educational programs in this area aimed at advancing standards of care.
The UCB Family Planning & Pregnancy initiative in immunological diseases aims to:
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people with severe diseases?”. We believe that this initiative has the potential to make a meaningful difference to the lives of many people living with immunological diseases today and in the future.
UCB is committed to comply with Industry self-regulated codes, including the EFPIA Code of Practice on Relationships Between the Pharmaceutical Industry and Patient Organisations.
In keeping with our transparency approach, support for patient organisations in Europe is disclosed here.